Welcome to our dedicated page for Sorrento Therapeutics news (Ticker: SRNEQ), a resource for investors and traders seeking the latest updates and insights on Sorrento Therapeutics stock.
Sorrento Therapeutics, Inc. (SRNEQ) is an antibody-centric, clinical-stage biopharmaceutical company striving to develop innovative therapies for cancer, inflammation, and autoimmune diseases. The company's primary focus lies in developing late-stage biosimilar and biobetter antibodies, along with clinical car-t therapies targeting solid tumors.
Sorrento is deeply dedicated to creating life-saving therapeutics to enhance patient outcomes. Their approach includes a diverse range of immuno-oncology platforms and assets like next-generation tyrosine kinase inhibitors, fully human antibodies, immuno-cellular therapies, antibody-drug conjugates, and oncolytic viruses. Additionally, Sorrento is actively working on antiviral therapies, vaccines against coronaviruses, and diagnostic solutions to combat critical diseases.
The company's commitment extends to developing innovative treatments for various medical conditions, such as advanced pain management offerings and solutions for cancer and autoimmune diseases. Sorrento has a rich pipeline of promising products under development, including novel pain management formulations, non-opioid treatments, and treatments for postherpetic neuralgia.
With a robust portfolio and a visionary approach to healthcare, Sorrento Therapeutics, Inc. stands at the forefront of cutting-edge biopharmaceutical research and development.
Sorrento Therapeutics, Inc. (OTC: SRNEQ) announced on April 25, 2023, that the U.S. Bankruptcy Court for the Southern District of Texas extended the restrictions on the transfer of shares for Scilex Holding Company, distributed as a dividend on January 19, 2023. This extension defers the selling, transferring, or disposing of these distributed shares from May 11, 2023, to September 1, 2023. The restrictions apply solely to the Distributed Stock and do not affect other Scilex securities held by Sorrento. Sorrento is focused on developing therapies for cancer, pain, and infectious diseases and has ongoing clinical trials for several novel products.
FAQ
What is the market cap of Sorrento Therapeutics (SRNEQ)?
What is Sorrento Therapeutics, Inc. (SRNEQ) known for?
What are some key products in Sorrento's portfolio?
How does Sorrento demonstrate its commitment to patient well-being?
What sets Sorrento Therapeutics, Inc. apart in the biopharmaceutical industry?
